Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT is a medical technology company.
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (2) Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (3) Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (4) Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (5) as a result of the foregoing, defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; and (6) as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against PROCEPT BioRobotics Corporation. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 22, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $2 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260727232489/en/
Media gallery
